Compare · ELYM vs TNYA
ELYM vs TNYA
Side-by-side comparison of Eliem Therapeutics Inc (ELYM) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELYM focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ELYM is the larger of the two at $224.9M, about 1.5x TNYA ($154.1M).
- TNYA has hit the wire 14 times in the past 4 weeks while ELYM has been quiet.
- TNYA has more recent analyst coverage (7 ratings vs 3 for ELYM).
- Company
- Eliem Therapeutics Inc
- Tenaya Therapeutics Inc.
- Price
- $5.11-0.97%
- $0.71+2.29%
- Market cap
- $224.9M
- $154.1M
- 1M return
- -
- -29.28%
- 1Y return
- -
- +2.21%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 0
- 14
- Recent ratings
- 3
- 7
Eliem Therapeutics Inc
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain epilepsy; and Anxiolytic for the treatment of generalized anxiety. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest ELYM
- SEC Form 8-K filed by Eliem Therapeutics Inc
- Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
- CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $9,741 worth of shares (1,191 units at $8.18), increasing direct ownership by 101% to 7,564 units (SEC Form 4)
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
- SEC Form 8-K filed by Eliem Therapeutics Inc
- SEC Form 4 filed by Chief Operating Officer Kaplan Brett
- SEC Form 3 filed by new insider Kaplan Brett
- SEC Form 8-K filed by Eliem Therapeutics Inc
- Eliem Therapeutics Announces Additions to its Leadership Team
- Amendment: SEC Form SC 13D/A filed by Eliem Therapeutics Inc
Latest TNYA
- Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
- SEC Form 4 filed by Director Williams R Sanders
- SEC Form 4 filed by Director Walsh Jeffrey T.
- SEC Form 4 filed by Director Stehman-Breen Catherine
- SEC Form 4 filed by Director Srivastava Deepak
- SEC Form 4 filed by Director Parschauer Karah Herdman
- SEC Form 4 filed by Director Lee June
- SEC Form 4 filed by Director Burroughs Amy L.
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders